| Year |
Citation |
Score |
| 2024 |
Morris M, Cook A, Dodkins J, Price D, Waller S, Hassan S, Nathan A, Aggarwal A, Payne HA, Clarke N, van der Meulen J, Nossiter J. What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England. Bmj Open. 14: e078284. PMID 38418235 DOI: 10.1136/bmjopen-2023-078284 |
0.441 |
|
| 2024 |
Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N, Sachdeva A. Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials. European Urology Oncology. PMID 38383277 DOI: 10.1016/j.euo.2024.01.016 |
0.352 |
|
| 2023 |
Dodkins J, Nossiter J, Cook A, Payne H, Clarke N, van der Meulen J, Aggarwal A. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. European Urology Oncology. PMID 37380578 DOI: 10.1016/j.euo.2023.05.002 |
0.393 |
|
| 2023 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Clarke N, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990). 185: 178-215. PMID 37003085 DOI: 10.1016/j.ejca.2023.02.018 |
0.538 |
|
| 2023 |
Attard G, Parry M, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, ... ... Clarke N, et al. Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. Research Square. PMID 36798177 DOI: 10.21203/rs.3.rs-2488586/v1 |
0.378 |
|
| 2022 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Clarke N, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology. PMID 36494221 DOI: 10.1016/j.eururo.2022.11.002 |
0.529 |
|
| 2022 |
Sachdeva A, Hart CA, Kim K, Tawadros T, Oliveira P, Shanks J, Brown M, Clarke N. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer. British Journal of Cancer. PMID 35869144 DOI: 10.1038/s41416-022-01914-3 |
0.401 |
|
| 2022 |
Dodkins J, Morris M, Nossiter J, van der Meulen J, Payne H, Clarke N, Aggarwal A. Practicalities, challenges and solutions to delivering a national organisational survey of cancer service and processes: lessons from the National Prostate Cancer Audit. Journal of Cancer Policy. 100344. PMID 35724956 DOI: 10.1016/j.jcpo.2022.100344 |
0.358 |
|
| 2022 |
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology. PMID 35450732 DOI: 10.1016/j.eururo.2022.04.002 |
0.54 |
|
| 2022 |
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, et al. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022]. European Urology. PMID 35440417 DOI: 10.1016/j.eururo.2022.04.004 |
0.519 |
|
| 2022 |
Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200208. PMID 35439030 DOI: 10.1200/JCO.22.00208 |
0.426 |
|
| 2022 |
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology. PMID 35393158 DOI: 10.1016/j.eururo.2022.02.010 |
0.433 |
|
| 2021 |
Aggarwal A, Nossiter J, Parry M, Sujenthiran A, Zietman A, Clarke N, Payne H, van der Meulen J. Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. The Lancet. Oncology. PMID 33676600 DOI: 10.1016/S1470-2045(20)30558-1 |
0.303 |
|
| 2020 |
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, et al. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903114. PMID 32552276 DOI: 10.1200/JCO.19.03114 |
0.4 |
|
| 2020 |
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology. PMID 32001144 DOI: 10.1016/J.Eururo.2020.01.012 |
0.476 |
|
| 2019 |
Clarke N, Payne H, van der Meulen J. Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.018. European Urology. PMID 31213325 DOI: 10.1016/j.eururo.2019.06.001 |
0.337 |
|
| 2019 |
Aggarwal AK, Sujenthiran A, Lewis D, Walker K, Cathcart P, Clarke N, Sullivan R, van der Meulen JH. Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population-based study. Cancer. PMID 30707779 DOI: 10.1002/cncr.31987 |
0.353 |
|
| 2018 |
Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, et al. Consensus on molecular imaging and theranostics in prostate cancer. The Lancet. Oncology. 19: e696-e708. PMID 30507436 DOI: 10.1016/S1470-2045(18)30604-1 |
0.386 |
|
| 2018 |
Clarke N. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? - Authors' reply. The Lancet. Oncology. 19: e438. PMID 30191845 DOI: 10.1016/S1470-2045(18)30616-8 |
0.423 |
|
| 2018 |
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology. PMID 29880291 DOI: 10.1016/S1470-2045(18)30365-6 |
0.396 |
|
| 2018 |
Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, Lau M, Maddineni S, Brown M, Clarke N. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. European Urology Focus. PMID 29699892 DOI: 10.1016/j.euf.2018.04.006 |
0.403 |
|
| 2018 |
Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, James N, Langley R, Parmar M. Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform. Bju International. PMID 29388336 DOI: 10.1111/bju.14153 |
0.422 |
|
| 2017 |
Aggarwal A, Lewis D, Charman SC, Mason M, Clarke N, Sullivan R, van der Meulen J. Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition. European Urology. PMID 28760646 DOI: 10.1016/j.eururo.2017.07.013 |
0.337 |
|
| 2017 |
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology. PMID 28655541 DOI: 10.1016/J.Eururo.2017.06.002 |
0.477 |
|
| 2017 |
Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, ... ... Clarke N, et al. Lipid degradation promotes prostate cancer cell survival. Oncotarget. PMID 28415728 DOI: 10.18632/Oncotarget.16123 |
0.448 |
|
| 2017 |
Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. European Urology. PMID 28189428 DOI: 10.1016/j.eururo.2017.01.039 |
0.458 |
|
| 2016 |
South A, Parulekar WR, Sydes MR, Chen BE, Parmar MK, Clarke N, Warde P, Mason M. Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. European Urology Focus. 2: 276-283. PMID 27766313 DOI: 10.1016/J.Euf.2015.11.004 |
0.43 |
|
| 2016 |
Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. European Urology. PMID 27450106 DOI: 10.1016/j.eururo.2016.07.015 |
0.468 |
|
| 2016 |
Delury C, Hart C, Brown M, Clarke N, Parkin E. Stroma-induced Jagged1 expression drives PC3 prostate cancer cell migration; disparate effects of RIP-generated proteolytic fragments on cell behaviour and Notch signaling. Biochemical and Biophysical Research Communications. 472: 255-61. PMID 26921446 DOI: 10.1016/j.bbrc.2016.02.101 |
0.377 |
|
| 2015 |
Tivesten Å, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urologic Oncology. PMID 26141678 DOI: 10.1016/j.urolonc.2015.05.030 |
0.382 |
|
| 2014 |
Cummings J, Sloane R, Morris K, Zhou C, Lancashire M, Moore D, Elliot T, Clarke N, Dive C. Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. Bmc Cancer. 14: 226. PMID 24674711 DOI: 10.1186/1471-2407-14-226 |
0.353 |
|
| 2014 |
Mottet N, Clarke N, De Santis M, Zattoni F, Morote J, Joniau S. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? Bju International. 115: 364-72. PMID 24628790 DOI: 10.1111/bju.12736 |
0.358 |
|
| 2014 |
Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, et al. The Melbourne Consensus Statement on the early detection of prostate cancer. Bju International. 113: 186-8. PMID 24206066 DOI: 10.1111/bju.12556 |
0.482 |
|
| 2013 |
Tawadros T, Alonso F, Jichlinski P, Clarke N, Calandra T, Haefliger JA, Roger T. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocrine-Related Cancer. 20: 137-49. PMID 23207293 DOI: 10.1530/ERC-12-0286 |
0.309 |
|
| 2011 |
Sydes MR, Egawa S, Sanders K, Amos C, Clarke N, Kimura T, James ND. Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: a randomized controlled trial for men with prostate cancer. International Journal of Urology : Official Journal of the Japanese Urological Association. 18: 553-4. PMID 21615523 DOI: 10.1111/j.1442-2042.2011.02783.x |
0.438 |
|
| 2009 |
Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. Bju International. 104: 1580-4. PMID 20053189 DOI: 10.1111/j.1464-410X.2009.08924.x |
0.324 |
|
| 2008 |
Koltz L, Clarke N. Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. European Urology. 53: 1079-83. PMID 18308462 DOI: 10.1016/j.eururo.2008.02.012 |
0.362 |
|
| 2007 |
Khafagy R, Shackley D, Samuel J, O'Flynn K, Betts C, Clarke N. Complications arising in the final year of life in men dying from advanced prostate cancer. Journal of Palliative Medicine. 10: 705-11. PMID 17592982 DOI: 10.1089/jpm.2006.0185 |
0.415 |
|
| 2004 |
Gazi E, Dwyer J, Lockyer N, Gardner P, Vickerman JC, Miyan J, Hart CA, Brown M, Shanks JH, Clarke N. The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer Faraday Discussions. 126: 41-59. PMID 14992399 |
0.354 |
|
| Show low-probability matches. |